Zydus Lifesciences Balance Sheet Health
Financial Health criteria checks 6/6
Zydus Lifesciences has a total shareholder equity of ₹221.0B and total debt of ₹7.9B, which brings its debt-to-equity ratio to 3.6%. Its total assets and total liabilities are ₹292.8B and ₹71.8B respectively. Zydus Lifesciences's EBIT is ₹45.4B making its interest coverage ratio -54. It has cash and short-term investments of ₹13.6B.
Key information
3.6%
Debt to equity ratio
₹7.86b
Debt
Interest coverage ratio | -54x |
Cash | ₹13.58b |
Equity | ₹221.02b |
Total liabilities | ₹71.79b |
Total assets | ₹292.81b |
Recent financial health updates
Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Jun 10Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Dec 27We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Jul 15Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly
Feb 15We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Nov 13Recent updates
Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 05Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
Jun 20Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Jun 10Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
May 25Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?
Mar 18Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%
Feb 28Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report
Feb 12Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Dec 27Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors
Dec 06With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case
Aug 23Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
Jul 17We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Jul 15Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's
Jun 24Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00
Jun 10Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
May 21Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly
Feb 15We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Nov 13Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Shares Could Be 23% Below Their Intrinsic Value Estimate
Aug 09Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 25Financial Position Analysis
Short Term Liabilities: ZYDUSLIFE's short term assets (₹114.2B) exceed its short term liabilities (₹53.4B).
Long Term Liabilities: ZYDUSLIFE's short term assets (₹114.2B) exceed its long term liabilities (₹18.4B).
Debt to Equity History and Analysis
Debt Level: ZYDUSLIFE has more cash than its total debt.
Reducing Debt: ZYDUSLIFE's debt to equity ratio has reduced from 67.9% to 3.6% over the past 5 years.
Debt Coverage: ZYDUSLIFE's debt is well covered by operating cash flow (410.5%).
Interest Coverage: ZYDUSLIFE earns more interest than it pays, so coverage of interest payments is not a concern.